Jun 23, 2026 06:52AM
Jun 18, 2026 07:01AM
Jun 18, 2026 07:00AM
May 11, 2026 04:01PM
Feb 9, 2026 04:01PM
Jan 9, 2026 03:09AM
Jan 8, 2026 07:07AM Enanta outlines 2026 milestones for RSV and immunology programs
Jan 8, 2026 07:00AM
Nov 17, 2025 04:01PM
Nov 14, 2025 02:39AM
Sep 30, 2025 04:20AM
Sep 29, 2025 06:30AM
Sep 29, 2025 06:30AM
Aug 11, 2025 04:02PM Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025
Aug 6, 2025 07:56PM
Jun 11, 2025 12:34PM
Jun 11, 2025 12:34PM
May 12, 2025 04:01PM
Feb 10, 2025 04:01PM
Dec 9, 2024 06:32AM
Dec 9, 2024 06:30AM Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)
Dec 6, 2024 05:00PM
Nov 25, 2024 04:01PM
Sep 26, 2024 06:02AM
Sep 26, 2024 06:00AM
Jan 4, 2024 07:00AM
Nov 20, 2023 04:01PM
Aug 7, 2023 04:01PM Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET
Jun 20, 2023 07:00AM
Jun 20, 2023 07:00AM
Apr 6, 2023 07:01AM
Apr 6, 2023 07:00AM
Jan 6, 2023 07:00AM
Nov 21, 2022 04:02PM
Nov 9, 2022 07:00AM Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
Oct 3, 2022 07:00AM
Aug 8, 2022 04:03PM
Aug 8, 2022 04:00PM
Aug 8, 2022 04:00PM
Jul 29, 2022 07:00AM
Jul 29, 2022 07:00AM
May 18, 2022 04:01PM Enanta Pharma (ENTA) Reports Topline Data from the RSVP Study of EDP-938
May 18, 2022 04:01PM
May 9, 2022 04:01PM
Mar 29, 2022 07:00AM
Mar 29, 2022 07:00AM
Feb 17, 2022 07:03AM
Feb 17, 2022 07:00AM
Feb 8, 2022 04:01PM Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET
Jan 6, 2022 07:00AM

324,250 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All